Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers

NCT04739917 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Malaria, Vivax

Interventions

BIOLOGICAL: Vaccine PvCS N+C+R 150 mcg
OTHER: Placebo SSN Montanide ISA-51 1 mL

Sponsor

Malaria Vaccine and Drug Development Center